-$0.54 Earnings Per Share Expected for Epizyme Inc (NASDAQ:EPZM) This Quarter

Share on StockTwits

Wall Street brokerages expect Epizyme Inc (NASDAQ:EPZM) to announce earnings per share of ($0.54) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Epizyme’s earnings. The highest EPS estimate is ($0.45) and the lowest is ($0.73). Epizyme also posted earnings per share of ($0.54) during the same quarter last year. The firm is scheduled to report its next earnings results on Friday, November 1st.

On average, analysts expect that Epizyme will report full year earnings of ($2.20) per share for the current financial year, with EPS estimates ranging from ($2.67) to ($1.89). For the next year, analysts expect that the business will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.56) to ($1.70). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Epizyme.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). The business had revenue of $5.90 million for the quarter, compared to the consensus estimate of $0.32 million. Epizyme’s revenue was down 50.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.42) EPS.

EPZM has been the subject of a number of analyst reports. BidaskClub downgraded shares of Epizyme from a “hold” rating to a “sell” rating in a report on Tuesday, September 24th. Zacks Investment Research downgraded shares of Epizyme from a “buy” rating to a “hold” rating and set a $15.00 price objective for the company. in a report on Wednesday, August 14th. HC Wainwright set a $25.00 price objective on shares of Epizyme and gave the stock a “buy” rating in a report on Monday, June 24th. Finally, ValuEngine downgraded shares of Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $17.25.

Large investors have recently added to or reduced their stakes in the company. Aperio Group LLC bought a new position in shares of Epizyme during the 2nd quarter worth about $72,000. Rockefeller Capital Management L.P. bought a new position in shares of Epizyme during the 2nd quarter worth about $88,000. United Services Automobile Association bought a new position in shares of Epizyme during the 2nd quarter worth about $134,000. HarbourVest Partners LLC bought a new position in Epizyme during the 2nd quarter valued at about $177,000. Finally, Harbourvest Partners LLC bought a new position in Epizyme during the 2nd quarter valued at about $177,000. 86.30% of the stock is owned by institutional investors.

Shares of NASDAQ:EPZM traded down $0.02 during midday trading on Monday, reaching $10.01. 340,515 shares of the company’s stock were exchanged, compared to its average volume of 821,450. The company’s 50 day simple moving average is $11.72 and its two-hundred day simple moving average is $12.60. The firm has a market capitalization of $908.09 million, a PE ratio of -5.82 and a beta of 2.37. Epizyme has a 12 month low of $5.14 and a 12 month high of $16.59. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.56 and a current ratio of 10.56.

Epizyme Company Profile

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Read More: How does new data get added to a blockchain?

Get a free copy of the Zacks research report on Epizyme (EPZM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CoStar Group Inc  Short Interest Up 29.1% in October
CoStar Group Inc Short Interest Up 29.1% in October
Short Interest in Cresud S.A.C.I.F. y A.  Grows By 18.2%
Short Interest in Cresud S.A.C.I.F. y A. Grows By 18.2%
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $448,000 Holdings in Dominion Energy Inc
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $448,000 Holdings in Dominion Energy Inc
Massachusetts Financial Services Co. MA Has $4.63 Billion Holdings in Visa Inc
Massachusetts Financial Services Co. MA Has $4.63 Billion Holdings in Visa Inc
Analysts Anticipate Store Capital Corp  Will Post Earnings of $0.48 Per Share
Analysts Anticipate Store Capital Corp Will Post Earnings of $0.48 Per Share
$0.47 Earnings Per Share Expected for Carbonite Inc  This Quarter
$0.47 Earnings Per Share Expected for Carbonite Inc This Quarter


© 2006-2019 Ticker Report